UKINETS bitesize guidance
Peri-operative management of patients with neuroendocrine or carcinoid tumours

**PAGE 1 - DIAGNOSIS AND TREATMENT ALGORITHM**

For further notes, including references, please see the following pages...

For more information, please visit our website: www.ukinets.org

**Surgical / Interventional Radiology procedure not related to tumour**

- **No Octreotide required**

**Minor procedure (surgery, biopsy, ablation) to primary tumour**

- **No Octreotide required**

**Major Surgery / TAE on metastatic deposits or bulky primary tumour**

- **Octreotide 100ug IV On induction**

**Non-functioning NET**

- **No Octreotide required**

**Octreotide 100ug IV On induction**

**Octreotide 12.5ug/hr IV infusion**

- **8-12 hours pre-operatively, 12-24 hours post procedure**

**Octreotide 25ug/hr IV infusion**

- **24 hours pre-operatively, then 24-48 hours post procedure**

**Octreotide 50ug/hr IV infusion**

- **24 hours pre-operatively, then 72 hours post procedure**

**History carcinoid syndrome**

- **Well controlled on SSA**

  - **Octreotide 12.5ug/hr IV infusion**
    - **8-12 hours pre-operatively, 12-24 hours post procedure**

**Active carcinoid syndrome**

- **Frequent symptoms despite SSA**

  - **Octreotide 25ug/hr IV infusion**
    - **24 hours pre-operatively, then 24-48 hours post procedure**

**Active carcinoid syndrome Symptomatic/ significant carcinoid heart disease**

- **Octreotide 50ug/hr IV infusion**
  - **24 hours pre-operatively, then 72 hours post procedure**

- **Octreotide 12.5ug/hr IV infusion**
  - **8-12 hours pre-operatively, 12-24 hours post procedure**

**No Octreotide required**

- **No Octreotide required**

**Octreotide 100ug IV On induction**

**Octreotide 12.5ug/hr IV infusion**

- **8-12 hours pre-operatively, 12-24 hours post procedure**

**Octreotide 25ug/hr IV infusion**

- **24 hours pre-operatively, then 24-48 hours post procedure**

**Octreotide 50ug/hr IV infusion**

- **24 hours pre-operatively, then 72 hours post procedure**
Peri-operative management of patients with neuroendocrine or carcinoid tumours

Octreotide 12.5ug/hr - octreotide 300ug in 250mls of 0.9% saline. Run at 10mls/hr.

Octreotide 25ug/hr – octreotide 600ug in 250mls of 0.9% saline. Run at 10mls/hr.

Octreotide 50ug/hr – octreotide 1200ug in 250mls of 0.9% saline. Run at 10mls/hr.

Regardless of chosen regimen: if signs of carcinoid syndrome (dry flushing, tachycardia, hypotension and wheeze caused by release of serotonin from tumours) are observed the patient should be given bolus octreotide 100mcgs IV to be repeated as required: this is the mainstay of treatment (continue or start background infusion 50mcg/hr).

If haemodynamic instability is encountered support from critical care/ICU should be requested urgently.

Drugs to consider using in a carcinoid crisis:

Hydrocortisone, ranitidine, chlorpheniramine (reduce histamine release)

Hypotension: IV fluids; consider phenylephrine, noradrenaline or vasopressin

Hypertension: optimise analgesia and anaesthesia (fentanyl/propofol), consider magnesium or GTN infusion in acute setting.

AVOID DRUGS THAT CAUSE HISTAMINE OR SEROTONIN RELEASE: thiopentone, suxamethonium, atracurium, morphine, tramadol, dopamine, isoprenaline

There has been very little good research into peri-operative management of patients with functional neuroendocrine tumours releasing carcinoid hormones. Studies that have been done differ in their definition of what constitutes an intra-operative carcinoid crisis (mainly through differences in duration of hypotensive episodes). This has resulted in differences in opinion over benefit of peri-operative octreotide in preventing carcinoid crises.

Anaesthetists should be prepared for carcinoid crisis even in patients on octreotide prophylaxis.

Carcinoid crisis can very rarely occur in patients without prior history of carcinoid syndrome on induction of anaesthesia.

References


For more information, please visit our website: www.ukinets.org